Fate Therapeutics
FATE
250 hedge funds and large institutions have $5.66B invested in Fate Therapeutics in 2021 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 96 increasing their positions, 73 reducing their positions, and 51 closing their positions.
78% more call options, than puts
Call options by funds: $18.9M | Put options by funds: $10.6M
32% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 73
0.92% more ownership
Funds ownership: 100.55% → 101.46% (+0.92%)
0% less capital invested
Capital invested by funds: $5.67B → $5.66B (-$8.76M)
6% less funds holding
Funds holding: 265 → 250 (-15)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
24% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$185M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$43.2M |
| 3 |
Morgan Stanley
New York
|
+$32.4M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$30.5M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$28.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$130M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$88.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$37.2M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$33.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.8M |
FATE Hedge Fund Activity: Q4 2021 in Review
250 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2021, worth a combined $5.66B — down 0.15% from $5.67B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of FATE and 39 opened new positions — a net loss of 12 holders — while 73 trimmed existing stakes and 96 added.
The largest buyer was Capital World Investors, opening a new position worth an estimated $185M. The largest seller was Lone Pine Capital, exiting entirely with an estimated $130M sold.
- 250 institutional investors held Fate Therapeutics (FATE) as of Q4 2021, down from 265 in Q3 2021.
- Funds reported $5.66B of Fate Therapeutics stock for Q4 2021, down 0.15% quarter-over-quarter.
- 39 funds opened new Fate Therapeutics positions in Q4 2021 and 51 closed out, a net change of -12 holders.
- The largest Fate Therapeutics buyer in Q4 2021 was Capital World Investors, an estimated $185M added.
- The largest Fate Therapeutics seller in Q4 2021 was Lone Pine Capital, an estimated $130M sold.
Based on aggregated 13F filings for Q4 2021.